Generalized myasthenia ... of all myasthenia gravis cases. The first one is an IgG1 [immunoglobulin G1] autoantibody against the acetylcholine receptor at the neuromuscular junction, AChR.

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Some drugs inhibit neuromuscular ... this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG.

Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease ... the approval of Argenx' neonatal FC receptor (FcRn) antibody Vyvgart (efgartigimod alfa).

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis ... pathological auto-antibodies that attack neuromuscular junctions ...

Myasthenia Gravis (MG) is a common neuromuscular junction disorder that is primarily mediated by anti-acetylcholine receptor antibodies (AChR-Ab). However, using AChR-Ab titers to predict MG severity ...

1 Department of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China 2 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China Myasthenia gravis (MG ... with ...

imm.ox.ac.uk Background: Myasthenia gravis ... of the neuromuscular junction. There is anecdotal evidence that the diagnosis is sometimes missed in older patients. Objective: To examine the incidence ...